Emergency FDA Recall Issued for ‘China-Made’ Cough Drops Sold Across the U.S.

If you grabbed a bag of cough drops at the pharmacy recently, it’s worth checking the label before popping one in your mouth. The FDA has issued a nationwide recall covering 15 cough drop products sold under five different brand names. All manufactured by a single company based in Xiamen, China. The recall affects flavors most Americans reach for without a second thought: honey lemon, cherry, menthol, vanilla honey, and creamy strawberry. The products were distributed across the entire country.

Who Made These, and Why Were They Recalled?

The company behind all 15 products is Xiamen Kang Zhongyuan Biotechnology Co., Ltd., headquartered in Xiamen, China. An FDA inspection of the manufacturing facility on August 15, 2025, turned up observations the agency described as potentially bearing on product quality. The company initiated a voluntary recall on March 20, 2026, following an FDA recommendation. On April 10, 2026, the FDA formally classified the recall as Class II. Critically, the FDA did not publicly disclose the specific findings from its August inspection leaving consumers without a clear explanation for what went wrong.

Five Brand Names, One Factory

The recall spans products sold under five distinct brand names: Exchange Select, Caring Mill, Discount Drug Mart Food Market, MGC Health, and QC Quality Choice. That variety of names on the shelf is the detail that catches many consumers off guard. These are not products from a single niche retailer. They appear in pharmacy chains, discount drug stores, and online health retailers. According to reporting by Today.com, no public press release was issued for this recall, meaning most consumers are being notified only through distributor letters rather than any public-facing announcement.

What Does a Class II Recall Actually Mean?

Most people see the word “recall” and assume the worst. The FDA’s Class II designation sits in the middle of a three-tier system. Class I is reserved for products that could cause serious injury or death. Class III covers minor labeling or packaging violations unlikely to cause harm. Class II, where this recall falls, means use of the product may cause temporary or medically reversible health effects, though the likelihood of serious harm is considered relatively low. In plain terms: the risk is real enough to act on, but the FDA does not consider it life-threatening for most people.

The Full List of Recalled Products and Lot Numbers

Consumers should check both the brand name and the lot number printed on their bag. The recalled Exchange Select products carry lot number 20241030. The Caring Mill cherry 90-count bag shares the same lot. Discount Drug Mart products in honey lemon and menthol also carry lot 20241030. MGC Health products span three lot numbers: 20240524, 20240720, and 20240730. QC Quality Choice products carry lot numbers 20240524 and 20240720, spanning multiple flavors including black cherry, creamy strawberry, vanilla honey, and menthol. All recalled products show expiration dates in 2026, meaning many are still within their use-by window.

Why the “Made in China” Label Matters Here

The recall arrives at a moment when American consumers are paying closer attention to where their everyday products are manufactured. China supplies a significant share of over-the-counter health products sold in the US under American-sounding brand names. In many cases, consumers have no easy way of knowing their drugstore staples are produced overseas. This recall makes that supply chain visible in a way that most routine purchases do not. The inspection that triggered this action took place in August 2025, roughly seven months before the recall was publicly announced and classified.

No One Has Publicly Said Anyone Got Sick

As of this reporting, the FDA has confirmed the recall but has not indicated that any consumers have suffered adverse health effects from the recalled products. The agency also has not provided specific details about what its inspectors found. That gap in information has left consumers in an uncomfortable position: they know enough to act, but not enough to understand what risk they are actually managing. Health experts advise that anyone who has used a recalled product and experienced unexpected symptoms, particularly those with underlying health conditions, should consult a healthcare provider.

What You Should Do Right Now

If you have any of the recalled products at home, the FDA and health authorities recommend not using them. Consumers can return the affected items to the store or retailer where they purchased them for a full refund, or dispose of the products safely. The lot numbers and UPC codes published in the FDA’s enforcement report are the most reliable way to confirm whether a specific bag is included. Because no press release was issued by the manufacturer, retailers and distributors have been reaching out directly through recall letters. The recall remains ongoing with no termination date announced.

A Pattern Americans Are Starting to Notice

This is not the first FDA recall triggered by concerns at a foreign manufacturing facility in recent months. The same week this cough drop recall was classified, the FDA also announced a separate recall of more than 3.1 million bottles of eye drops made by a California-based company, involving potential sterility concerns. Recalls linked to overseas manufacturing inspections have become a recurring feature of FDA enforcement activity. Consumer advocacy groups have long called for greater transparency in how the FDA communicates recall information to the public, particularly when no formal press release accompanies a nationwide action.

The Bigger Question Behind a Bag of Cough Drops

A voluntary recall of cough drops might seem like a minor story. But it touches something Americans are actively wrestling with: how much do we know about what is in the products we buy at our local pharmacy? The brand on the front of the bag is not always the company that made it. The flavors are familiar, the packaging looks domestic, and the prices are budget-friendly. Behind that, in this case, was a factory in China that failed an FDA inspection. Whether the specific risk here proves to be minor or significant, the question of pharmaceutical supply chain transparency is not going away.